Global Hemp Group ("GHG") is a Canadian publicly traded company focused on two key business segments - Industrial Hemp and Health & Wellness (Biopharma):

Industrial Hemp: This division's primary focus lies in the environmental uses of hemp for construction and hemp for sustainable bio-energy sources, both contributing to a carbon-negative footprint.

Biopharma: The Health and Wellness Division is focused on the acquisition of exclusive licensing of patents and IP. To date the Company has executed agreements for partnerships with Serres Thériault (2021) Inc. ("STI"), and Apollon Formularies plc.

The Company's **R&D Division**, lead by Prof. Víctor M. Castaño, a prominent figure in applied science and technology from the National Autonomous University of Mexico, focuses on GHG's broader strategy to leverage the growing opportunities in the industrial hemp sector.

Most recently, GHG executed an Amended Exclusive Option Agreement ("Agreement") with STI, a New Brunswick ("NB") multi-facetted, vertically integrated cannabis operator with additional focus on hemp.

The Agreement provides GHG with a 15% interest in STI as well as more time and flexibility to fully conclude its full acquisition of STI should the Company decide to exercise its option. This transaction provides GHG with a clear pathway to further diversify its activities in the industry and importantly, collaborate with a licensed entity.

Since the execution of the initial EOA in January 2024, STI accomplished the following over the last year:

- received a license upgrade
- began active sales to Cannabis New Brunswick
- opened an onsite Farmgate retail store
- has an initial 21 product SKUs actively listed for sale
- finalized all security system upgrades in order to become a Standard Licensed Producer
- has successfully cultivated 2-acres of a high yielding registered CBD hemp cultivar

The Company continues to work to expand these and other opportunities in its various business segments.



Capital Structure

Jan 24/25

Shares Issued & Outstanding

34,883,787

Warrants (10.9 MM @ \$0.10, 1.9 yrs remaining)

12,122,329

Options (ave. \$1.06, 1 yr remaining)

(1.18 MM ave. \$1.02, 1.2 yrs remaining)

707,500

Trading CSE: GHG / OTCPK: GBHPF / FRANKFURT: GHG0

Management, Directors, and Advisors

Curt Huber Interim Pres/CEO/Director
Christopher Cheery, CPA, CA
Ramsey Douglas Director
Aurelio Useche, MBA, CPA Director

Nikolas Perrault, CFA

Mathieu Couillard, MBA

Prof. Victor Castano, Ph.D.

Paul Perrault, Ph.D.

Special Advisor / Capital Markets Advisor Bus Dev & Cap Markets Advisor, Head of R&D Division Advisor, Industrial Hemp

Hemp Based Sustainable Energy Products

Hemp cultivation is a potent carbon sink, capturing more CO_2 per hectare than forests, making it a valuable tool in climate solutions. Its biomass offers sustainable energy potential and exceptional carbon sequestration. GHG, through its affiliate STI, collaborated with Groupe Savoie to cultivate 35 acres of industrial hemp in New Brunswick. This partnership focuses on torrefaction and pelletization to overcome logistical challenges in sustainable energy. Hemp biomass, similar in calorific value to wood, is ideal for this process, resulting in denser products with improved storage and transportability.

GHG aims to commercialize this technology in European markets and is sourcing equipment for biochar development to maximize carbon credits. This initiative aligns with the growing demand for sustainable biomass energy solutions. GHG's commitment to harnessing hemp for sustainable energy and construction demonstrates its dedication to innovation and environmental stewardship.

Empowering a greener future with hemp-based energy and sustainable housing solutions



Exclusive Option Agreement

In January 2025 GHG executed an Amendment and Extension to its Exclusive Option Agreement to

acquire STI. The Agreement covers the acquisition of the 8.6-acre compound and its five buildings (with the property independently valued at \$1,401,000 as at September 3, 2024) for processing, packaging and sales, along with 6,000 square feet of greenhouse, equipment, inventory, and a Farmgate retail operation located within the existing compound that will have exclusive distribution of products manufactured by STI, plus the following:

- Health Canada Licenses
- Exclusive partnership deal with Hemp License holder
- Exclusive partnership deal with Cannabis Research
 License holder
- Intellectual Property relating to cannabis recipes
- Partnerships with strain developers of genetics including strains with high value CBD, CBG, CBN, and THVC

Looking into 2025

In the first quarter of 2025, STI will expand its offerings by entering the broader cannabis markets across the Maritimes, enhancing its market presence. By the second quarter of 2025, STI is set to finalize its transition from a Micro Processing, Packaging, and Sales license to becoming a Standard Licensed Producer, which will enable it to scale operations and meet increased regulatory requirements.

Recent Announcements

Jan 17, 2025 - <u>GHG Announces Closing of the 1st Tranche</u> of its Private Placement and Issuance of Common Shares

Jan 10, 2025 - GHG Announces Debt Settlement, Update to its Amended Option Agreement and Private Placement

Jan 7, 2025 - GHG Provides Corporate Update

Dec 11, 2024 - Global Hemp Group Early Warning Report

Aug 23, 2024 - GHG Welcomes Christopher Cherry as its New CFO

Creating a Hemp Agro-Industrial Zone in the province of Quebec

The principal feature of the Hemp Agro-Industrial Zone ("HAIZ") concept is the proximity of the industrial plant to the supply of raw materials and final markets. This is particularly true with the choice of which is close to farming, available industrial park space, and is in the region where there is a desire to create affordable housing where manufactured products can be utilized. GHG has now assembled a team committed to the concept of durable construction to implement this project.

The Company expects to provide updates on this business segment in Q1 2025.

GHG acquired the Exclusive Perpetual License for North America (the United States, Canada and Mexico) to certain **Apollon Formularies plc** intellectual property and proprietary technology, including, but not limited to, four key patents and all associated preclinical and clinical data relating to the patents and proprietary technology (the "IP").

- Compositions and Methods for Treatment of Cancers
- Compositions and Methods for Treatment of Inflammation
- Methods for Treatment of Human Cancers Using Cannabis Compositions
- Methods for Treatment of Human Cancers Using Mushroom Compositions
- BIOENSIS Preclinical Data reflecting independent 3D cell culture testing of cannabis and mushroom formulations included in the patent applications

These international patents include claims to the treatments of cancers and inflammatory conditions using natural biologics that have been shown in independent, third-party pre-clinical 3D cell culture testing at BIOENSIS laboratories in the United States to kill cancer cells via direct cytotoxicity and immune stimulated cytotoxicity with high efficacy.

